Head-to-head · free

NanoViricides, Inc. vs Novartis AG

NNVC vs NVS — return on capital, cash generation, margins and balance sheet side by side.

NNVC

0 / 0

measures where NNVC leads

NVS

0 / 0

measures where NVS leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasureNNVC · FY2026NVS
Revenue——
Net income(8.2M)—
Revenue growth (yearly, multi-year)——
Free cash flow(7.8M)—
Free cash flow margin——
Net cash / (debt)——
ROIC—18.6%
Return on equity—31.0%
Gross margin—75.8%
Operating margin—31.1%
Net debt / EBITDA—0.96x

Figures are as reported by each company; latest fiscal year shown.

Where NanoViricides, Inc.'s cash went (FY2026)

Capital spending
$84317
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full NNVC profile →

Where Novartis AG's cash went

Not reported yet.

Full NVS profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons